Alps Group Inc is an integrated biotechnology platform focused on advanced therapies. The company (ALPS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alps Group Inc is an integrated biotechnology platform focused on advanced therapies. The company (ALPS) trades at $0.58 with AI Score 46/100 (Grade C). Alps Group Inc is an integrated biotechnology platform based in Kuala Lumpur, focusing on advanced therapies. Market cap: $97.06M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for ALPS: ALPS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALPS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ALPS: the 1 perspectives are evenly split.
How is this calculated? →Alps Group Inc is an integrated biotechnology platform focused on advanced therapies. The company (ALPS) Healthcare & Pipeline Overview
Alps Group Inc, an integrated biotechnology platform, focuses on research and development, medical services, and wellness solutions within the advanced therapies sector. Headquartered in Kuala Lumpur, the company aims to create a fair healthcare ecosystem with accessible predictive, preventive, and precision medicine.
What Is the Investment Thesis for ALPS?
Alps Group Inc presents a unique investment opportunity within the biotechnology sector, focusing on advanced therapies and integrated healthcare solutions. With a market capitalization of $97.06M, the company operates with a high-risk, high-reward profile, indicated by a negative profit margin of -2004.5%. Key value drivers include the potential for innovative breakthroughs in its research and development activities and the expansion of its medical services and wellness solutions. Growth catalysts include strategic partnerships, successful clinical trials, and regulatory approvals for its advanced therapies. However, investors should be aware of potential risks, including the company's negative profitability, reliance on research outcomes, and competition within the biotechnology industry. The company's beta of 0.25 suggests lower volatility compared to the market, but the absence of a dividend yield reflects its focus on reinvesting earnings for growth.
Based on FMP financials and quantitative analysis
ALPS Key Highlights
- Market capitalization of $97.06M indicates the company's current valuation in the biotechnology market.
- Gross margin of 38.6% reflects the company's efficiency in converting revenue into profit after accounting for the cost of goods sold.
- Profit margin of -2004.5% highlights significant losses relative to revenue, indicating potential challenges in achieving profitability.
- Beta of 0.25 suggests lower volatility compared to the overall market, potentially offering a more stable investment.
- Focus on advanced therapies positions the company in a high-growth area within the biotechnology sector.
Who Are ALPS's Competitors?
ALPS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALPS's Key Strengths?
- Integrated biotechnology platform.
- Focus on advanced therapies.
- Commitment to accessible healthcare.
- Research and development capabilities.
What Are ALPS's Weaknesses?
- Negative profit margin.
- Small employee base.
- Limited market presence.
- Reliance on research outcomes.
What Could Drive ALPS Stock Higher?
- Clinical trial results for advanced therapies may drive investor interest and stock appreciation.
- Regulatory approvals for new medical devices or treatments can expand market access and revenue potential.
- Strategic partnerships with pharmaceutical companies or research institutions can accelerate product development and commercialization.
What Are the Key Risks for ALPS?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Negative profit margin may hinder the company's ability to fund research and development activities.
- Competition from larger biotechnology companies with greater resources may limit market share and growth opportunities.
- Regulatory changes and compliance requirements in the healthcare industry may increase operating costs and delay product approvals.
What Are the Growth Opportunities for ALPS?
- Expansion into New Therapeutic Areas: Alps Group Inc has the opportunity to expand its research and development efforts into new therapeutic areas, such as oncology, neurology, and infectious diseases. The global market for cancer therapies, for example, is projected to reach hundreds of billions by 2030. By diversifying its research portfolio, Alps Group Inc can reduce its reliance on specific therapeutic areas and capitalize on emerging market opportunities, potentially leading to significant revenue growth and increased market share.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with pharmaceutical companies, research institutions, and technology providers can accelerate Alps Group Inc's research and development efforts and expand its market reach. Collaborations can provide access to new technologies, funding, and expertise, enabling the company to develop and commercialize its advanced therapies more efficiently. These partnerships can also enhance Alps Group Inc's credibility and attract further investment, driving long-term growth and innovation.
- Geographic Expansion into Emerging Markets: Expanding its operations into emerging markets, particularly in Asia and Latin America, can provide Alps Group Inc with access to new customer segments and revenue streams. These markets often have unmet healthcare needs and a growing demand for advanced therapies and wellness solutions. By establishing a presence in these regions, Alps Group Inc can capitalize on the increasing healthcare spending and improve its global market position, driving sustainable growth and profitability.
- Development of Personalized Medicine Solutions: Investing in the development of personalized medicine solutions, such as diagnostic tests and targeted therapies, can differentiate Alps Group Inc from its competitors and attract a growing segment of healthcare consumers. Personalized medicine leverages an individual's genetic information to tailor treatments and improve outcomes. As the cost of genetic sequencing decreases and the understanding of genomics increases, the demand for personalized medicine solutions is expected to grow significantly, creating a substantial market opportunity for Alps Group Inc.
- Integration of Digital Health Technologies: Incorporating digital health technologies, such as telehealth platforms, wearable devices, and mobile health apps, can enhance Alps Group Inc's service offerings and improve patient engagement. Digital health technologies can facilitate remote monitoring, personalized coaching, and data-driven insights, leading to better health outcomes and increased customer satisfaction. By integrating these technologies into its healthcare ecosystem, Alps Group Inc can create a more comprehensive and accessible suite of services, driving customer loyalty and revenue growth.
What Opportunities Does ALPS Have?
- Expansion into new therapeutic areas.
- Strategic partnerships and collaborations.
- Geographic expansion into emerging markets.
- Development of personalized medicine solutions.
What Threats Does ALPS Face?
- Competition from established biotechnology companies.
- Regulatory hurdles and compliance requirements.
- Economic downturns affecting healthcare spending.
- Patent expirations and intellectual property risks.
What Are ALPS's Competitive Advantages?
- Integrated biotechnology platform combining research, medical services, and wellness solutions.
- Focus on advanced therapies and personalized medicine.
- Commitment to creating a fair and accessible healthcare ecosystem.
What Does ALPS Do?
Alps Group Inc, based in Kuala Lumpur, Malaysia, is an integrated biotechnology platform dedicated to advancing healthcare through research and development, medical services, and wellness solutions. The company focuses on advanced therapies, aiming to create a healthcare ecosystem that emphasizes predictive, preventive, and precision medicine. Alps Group Inc operates with a vision of making healthcare more accessible and equitable. The company's activities span across several key areas, including biotechnology research, medical service delivery, and the development of wellness solutions. These activities are all geared towards providing advanced therapies that address a range of medical needs. Alps Group Inc aims to be at the forefront of medical innovation, contributing to the development of new treatments and healthcare strategies. The company's integrated approach allows it to combine research insights with practical medical applications, enhancing the effectiveness and accessibility of its offerings. Alps Group Inc is committed to improving patient outcomes and promoting overall well-being through its diverse range of healthcare solutions.
What Products and Services Does ALPS Offer?
- Conducts research and development in advanced therapies.
- Provides medical services focused on predictive, preventive, and precision medicine.
- Develops and offers wellness solutions.
- Aims to create a fair and accessible healthcare ecosystem.
- Integrates biotechnology with medical service delivery.
- Focuses on improving patient outcomes through innovative treatments.
How Does ALPS Make Money?
- Generates revenue through research and development activities.
- Provides medical services and wellness solutions to patients.
- Aims to commercialize advanced therapies and healthcare technologies.
What Industry Does ALPS Operate In?
Alps Group Inc operates within the biotechnology industry, a sector characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The global biotechnology market is projected to reach significant growth in the coming years, driven by advancements in genomics, personalized medicine, and biopharmaceuticals. Companies in this sector face intense competition from both established pharmaceutical giants and emerging biotech firms. Alps Group Inc's focus on integrated healthcare solutions and advanced therapies positions it to capitalize on the growing demand for innovative medical treatments and wellness programs.
Who Are ALPS's Key Customers?
- Patients seeking advanced medical treatments.
- Individuals interested in wellness solutions.
- Healthcare providers and institutions.
- Research partners and collaborators.
Company Profile
Alps Group Inc is an integrated biotechnology platform focused on advanced therapies. The company operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kuala Lumpur, MY. The company is led by CEO Seng Kong Tham. ALPS has traded publicly since 2025.
Alps Group Inc is an integrated biotechnology platform focused on advanced therapies. The company (ALPS) Valuation Context
Valued at $97.06M, ALPS is classified as a micro-cap stock. Relative to its peer group, ALPS's quantitative score of 46/100 is below the peer average of 76/100.
Key Financial Metrics
Its free cash flow yield is -0.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 3/9Financial Health
Alps Group Inc is an integrated biotechnology platform focused on advanced therapies. The company's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ALPS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its growth potential.
- Social sentiment has shifted positively, with increased discussions around the company's innovative therapies and their potential impact on the biotech sector.
- The ongoing advancements in their research and development have sparked excitement among investors, particularly in light of recent breakthroughs.
- Partnership announcements with established firms have bolstered market perception, positioning Alps Group as a serious player in advanced biotechnology.
Bear Case
- Despite positive sentiment, there are concerns about the long timeline for regulatory approvals, which could delay potential revenue streams.
- Community discussions have highlighted skepticism regarding the scalability of their therapies, raising doubts about long-term viability.
- The biotech sector's volatility can lead to sudden shifts in investor sentiment, and recent market trends have shown increased bearishness in the sector overall.
- Insider selling activity in the past month has raised eyebrows, leading some to question the company's short-term outlook and the confidence of its leadership.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $3M | -$65M | -$14.11 |
Based on FMP financials and quantitative analysis
ALPS Latest News
-
Why Leifras Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
benzinga · Jun 24, 2026
-
Why Did Alps Group (ALPS) Stock Jump Over 15% After Hours?
benzinga · Jun 24, 2026
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Jun 23, 2026
-
Reported Earlier: Alps Group Rolling Out Internal Patient-Derived Organoid Program For Personalized Cancer Treatment In Partnership With Dr. Kong Wai Mun Of Axiocell Biotech
benzinga · Jun 23, 2026
ALPS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALPS.
Price Targets
Wall Street price target analysis for ALPS.
ALPS MoonshotScore
What does this score mean?
The MoonshotScore rates ALPS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Why Leifras Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Why Did Alps Group (ALPS) Stock Jump Over 15% After Hours?
12 Health Care Stocks Moving In Tuesday's After-Market Session
Reported Earlier: Alps Group Rolling Out Internal Patient-Derived Organoid Program For Personalized Cancer Treatment In Partnership With Dr. Kong Wai Mun Of Axiocell Biotech
Leadership: Seng Kong Tham
CEO
Seng Kong Tham is the CEO of Alps Group Inc, where he manages a team of two employees. Details regarding his prior experience and educational background are not available. As the CEO, he is responsible for the overall strategic direction and operational management of the company, focusing on advancing its mission of providing integrated biotechnology solutions and promoting accessible healthcare.
Track Record: Due to limited information, Seng Kong Tham's specific achievements and milestones at Alps Group Inc are not available. His leadership is focused on guiding the company's research and development efforts and expanding its market presence within the biotechnology sector.
Common Questions About ALPS (Healthcare)
What does Alps Group Inc do?
Alps Group Inc operates as an integrated biotechnology platform, focusing on the research, development, and delivery of advanced therapies. The company aims to create a fair healthcare ecosystem by providing accessible predictive, preventive, and precision medicine solutions. Alps Group Inc's activities span biotechnology research, medical service delivery, and the development of wellness solutions, all geared towards improving patient outcomes and promoting overall well-being. The company is based in Kuala Lumpur, Malaysia.
What do analysts say about ALPS stock?
Given the limited information available and the company's small size, there is no readily available analyst coverage or consensus on Alps Group Inc. Potential investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. The company's market capitalization is $0.17 billion, and it operates with a negative profit margin of -2004.5%.
What are the main risks for ALPS?
Alps Group Inc faces several key risks, including its negative profit margin, which may limit its ability to fund research and development activities. The company also faces competition from larger, more established biotechnology companies with greater resources. Regulatory changes and compliance requirements in the healthcare industry could increase operating costs and delay product approvals. Additionally, the success of Alps Group Inc depends on the outcomes of its research and development efforts, which are inherently uncertain.
What are the key factors to evaluate for ALPS?
Alps Group Inc is an integrated biotechnology platform focused on advanced therapies. The company (ALPS) holds an AI score of 46/100 (low). Not financial advice.
How frequently does ALPS data refresh on this page?
ALPS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ALPS's recent stock price performance?
Alps Group Inc is an integrated biotechnology platform focused on advanced therapies. The company (ALPS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated biotechnology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALPS overvalued or undervalued right now?
Valuing Alps Group Inc is an integrated biotechnology platform focused on advanced therapies. The company (ALPS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ALPS?
Before investing in Alps Group Inc is an integrated biotechnology platform focused on advanced therapies. The company (ALPS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Alps Group Inc.
- Financial data may not be comprehensive.
- Analysis based on provided sources and publicly available information.